Newsflash:
- Many Drug Labels Missing Dose, Safety Info for Kids
- Lilly Oncology to Highlight Final Results for Phase III Study in Most Common Form of Lung Cancer
- J&J Opens Doxil Rationing Program to New Patients
- FDA Issues Safety Label Changes for Fingolimod
- FDA Backs Pill to Block HIV Infection
- FDA Advisers Recommend Approving Arena Weight-Loss Drug
UK Body Recommends Lilly, Amylin Diabetes Drug Bydureon
Dow Jones Newswires (01/12/12) Stovall, Sten
The U.K.'s healthcare cost-effectiveness body has confirmed initial guidance recommending Eli Lilly and Amylin Pharmaceuticals' Type 2 diabetes drug Bydureon for use in the U.K.'s publicly funded National Health Service. The National Institute for Health and Clinical Excellence, or NICE, said the injectable medicine, known generically as exenatide, could be given in combination with certain other drugs in obese patients with a body mass index above 35, or those for whom insulin injections wouldn't be suitable.
Abstract News © Copyright 2011
INFORMATION, INC.
Sponsor Highlights
Our Sponsors:
Sitemap
© Pharmacist e-Link
